ANDA Backlog: FDA Climbs The Mountain, Will Need To Climb It Again
Agency has acted on 84% of generic applications pending when user fee program launched, but most actions were 'complete response' letters, which do not reduce review workload.
Agency has acted on 84% of generic applications pending when user fee program launched, but most actions were 'complete response' letters, which do not reduce review workload.